 |
 |
| Mauna Kea's managers say that their new strategic approach to sell through licensing agreements is benefiting the company's financial performance, although the firm's stock price continues to fall on the Euronext stock exchange. This image shows physicians using the confocal laser endomicroscopy 'optical biopsy' platform to make diagnoses. Photo: Mauna Kea Technologies. |
| © 2023 SPIE Europe |
|
